Clinical Trial Update: Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib [Phase 2]

View source ↗

Summary

Phase 2 trial update comparing osimertinib plus chemotherapy versus osimertinib alone in EGFR-mutant non-small cell lung cancer with persistent week-3 ctDNA EGF…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: Beijing Cancer Prevention & Treatment Society | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING